{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:26:42Z","timestamp":1785346002215,"version":"3.55.0"},"reference-count":43,"publisher":"PAGEPress Publications","issue":"3","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Introduction: Platelet-rich plasma (PRP) has shown positive effects on enhancing erectile function in animal studies. Human clinical trials are limited and provide contradictory results. This review aims to conduct a meta-analysis of the available Randomized controlled trials (RCT) to assess the efficacy of PRP in males with ED. Methods: A systematic review was carried out following the Cochrane Handbook of Intervention and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and registered in PROSPERO (CRD42023441655).Results: A total of three RCTs were included in the analysis for a total of 221 patients with mild to moderate ED. The patients receiving PRP reported significantly better improvement of IIEFEF score during 1,3- and 6-months follow-up compared to the placebo group (mean difference [MD] 2.66, 95% confidence interval [CI] 1.48 to 3.83, p &lt; 0.01; MD 2.11, 95%CI 0.13 to 4.09, p = 0.04; MD 2.99, 95%CI 1.79 to 4.19, p &lt; 0.01). The pooled analysis indicated that attainment of minimally clinical important difference (MCID) was significantly higher in patients receiving PRP compared to the placebo group during one and 6-month follow-up (odds ratio [OR] 5.51, 95%CI 1.2 to 254, p = 0.03; OR 5.64, 95%CI 2.05 to 15.55, p &lt; 0.01; respectively). Encouragingly, no major AEs were reported in all three trials in the PRP and placebo groups (p = 0.99). Conclusions: This review highlights the potential role of PRP in providing short-term improvement of erectile function parameters for up to 6 months in mild to moderate ED patients. Future RCTs with longer-duration follow-ups and more standardized treatment protocols are necessary to gain sufficient details on PRP's long-term effectiveness and safety.<\/jats:p>","DOI":"10.4081\/aiua.2024.12687","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:16:52Z","timestamp":1727936212000},"source":"Crossref","is-referenced-by-count":4,"title":["The potential role of intracavernosal injection of platelet-rich plasma for treating patients with mild to moderate erectile dysfunction: A GRADE-Assessed systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.4081","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-0411","authenticated-orcid":false,"given":"Niwanda","family":"Yogiswara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikri","family":"Rizaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ayodhia","family":"Soebadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"144994","doi-asserted-by":"crossref","unstructured":"Kessler A, Sollie S, Challacombe B, et al. The global prevalence of erectile dysfunction: a review. BJU Int 2019; 124:587-99.","DOI":"10.1111\/bju.14813"},{"key":"144995","doi-asserted-by":"crossref","unstructured":"Fisher WA, Eardley I, McCabe M, Sand M. Erectile dysfunction (ED) is a shared sexual concern of couples I: couple conceptions of ED. J Sex Med 2009; 6:2746-60.","DOI":"10.1111\/j.1743-6109.2009.01457.x"},{"key":"144996","doi-asserted-by":"crossref","unstructured":"Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology Guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol 2021; 80:333-57.","DOI":"10.1016\/j.eururo.2021.06.007"},{"key":"144997","doi-asserted-by":"crossref","unstructured":"Pastuszak AW. Current diagnosis and management of erectile dysfunction. Curr Sex Health Rep 2014; 6:164.","DOI":"10.1007\/s11930-014-0023-9"},{"key":"144998","doi-asserted-by":"crossref","unstructured":"Lowy M, Ramanathan V. Erectile dysfunction: causes, assessment and management options. Aust Prescr 2022; 45:159.","DOI":"10.18773\/austprescr.2022.051"},{"key":"144999","doi-asserted-by":"crossref","unstructured":"Kim SC, Lee YS, Seo KK, et al. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. Int J Impot Res 2014; 26:87.","DOI":"10.1038\/ijir.2013.41"},{"key":"145000","doi-asserted-by":"crossref","unstructured":"Chung DY, Ryu JK, Yin GN. Regenerative therapies as a potential treatment of erectile dysfunction. Investig Clin Urol 2023; 64:312.","DOI":"10.4111\/icu.20230104"},{"key":"145001","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Aizpurua X, Garranzo-Ibarrola M, Sim\u00f3n-Rodr\u00edguez C, et al. Stem cell therapy for erectile dysfunction: a step towards a future treatment. Life (Basel). 2023;13:502.","DOI":"10.3390\/life13020502"},{"key":"145002","doi-asserted-by":"crossref","unstructured":"Brunckhorst O, Wells L, Teeling F, et al. A systematic review of the long-term efficacy of low-intensity shockwave therapy for vasculogenic erectile dysfunction. Int Urol Nephrol 2019;51:773.","DOI":"10.1007\/s11255-019-02127-z"},{"key":"145003","doi-asserted-by":"crossref","unstructured":"Pavlovic V, Ciric M, Jovanovic V, Stojanovic P. Platelet rich plasma: a short overview of certain bioactive components. Open Medicine 2016;11:242.","DOI":"10.1515\/med-2016-0048"},{"key":"145004","doi-asserted-by":"crossref","unstructured":"Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39:2135-40.","DOI":"10.1177\/0363546511417792"},{"key":"145005","doi-asserted-by":"crossref","unstructured":"Liao CH, Lee KH, Chung SD, et al. Intracavernous injection of platelet-rich plasma therapy enhances erectile function and decreases the mortality rate in streptozotocin-induced diabetic rats. Int J Mol Sci. 2022; 23:3017.","DOI":"10.3390\/ijms23063017"},{"key":"145006","doi-asserted-by":"crossref","unstructured":"Huang YC, Wu CT, Chen MF, et al. Intracavernous injection of autologous platelet-rich plasma ameliorates hyperlipidemia-associated erectile dysfunction in a rat model. Sex Med. 2021;9:100317.","DOI":"10.1016\/j.esxm.2020.100317"},{"key":"145007","doi-asserted-by":"crossref","unstructured":"Tai HC, Tsai WK, Chang ML, et al. Intracavernous injection of platelet-rich plasma reverses erectile dysfunction of chronic cavernous nerve degeneration through reduction of prostate hyperplasia evidence from an aging-induced erectile dysfunction rat model. FASEB J. 2023;37:e22826.","DOI":"10.1096\/fj.202201443R"},{"key":"145008","doi-asserted-by":"crossref","unstructured":"Shaher H, Fathi A, Elbashir S, et al. Is Platelet rich plasma safe and effective in treatment of erectile dysfunction? Randomized controlled study. Urology 2023; 175:114-9.","DOI":"10.1016\/j.urology.2023.01.028"},{"key":"145009","doi-asserted-by":"crossref","unstructured":"Masterson TA, Molina M, Ledesma B, et al. Platelet-rich plasma for the treatment of erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled clinical trial. J Urol 2023; 210:154-61.","DOI":"10.1097\/JU.0000000000003481"},{"key":"145010","doi-asserted-by":"crossref","unstructured":"Poulios E, Mykoniatis I, Pyrgidis N, et al. Platelet-rich plasma (PRP) improves erectile function: a double-blind, randomized, placebo-controlled clinical trial. J Sex Med 2021;18:926-35.","DOI":"10.1016\/j.jsxm.2021.03.008"},{"key":"145011","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane Book Series. The Cochrane Collaboration and John Wiley & Sons Ltd.; 2008.","DOI":"10.1002\/9780470712184"},{"key":"145012","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"145013","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"145014","doi-asserted-by":"crossref","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 2014;14:135.","DOI":"10.1186\/1471-2288-14-135"},{"key":"145015","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924.","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"145016","doi-asserted-by":"crossref","unstructured":"Balshem H, Helfand M, Schu\u0308nemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"145017","doi-asserted-by":"crossref","unstructured":"Raheem OA, Natale C, Dick B, et al. Novel treatments of erectile dysfunction: review of the current literature. Sex Med Rev 2021; 9:123-32.","DOI":"10.1016\/j.sxmr.2020.03.005"},{"key":"145018","doi-asserted-by":"crossref","unstructured":"Man L, Li G. Low-intensity extracorporeal shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Urology 2018; 119:97-103.","DOI":"10.1016\/j.urology.2017.09.011"},{"key":"145019","doi-asserted-by":"crossref","unstructured":"Zou ZJ, Tang LY, Liu ZH, et al. Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis. International Braz J Urol 2017; 43:805-21.","DOI":"10.1590\/s1677-5538.ibju.2016.0245"},{"key":"145020","doi-asserted-by":"crossref","unstructured":"Yao H, Wang X, Liu H, et al. Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction. Am J Mens Health 2022;16:15579883221087532.","DOI":"10.1177\/15579883221087532"},{"key":"145021","doi-asserted-by":"crossref","unstructured":"Campbell JD, Trock BJ, Oppenheim AR, et al. Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. Ther Adv Urol 2019;11:1-13.","DOI":"10.1177\/1756287219838364"},{"key":"145022","unstructured":"Salonia A, Bettocchi C, Carvalho J, et al. Sexual and reproductive health. EAU Guidelines. Proceedings EAU Annual Congress, Amsterdam; 2021."},{"key":"145023","doi-asserted-by":"crossref","unstructured":"Francomano D, Iuliano S, Deh\u00f2 F, et al. Regenerative treatment with platelet-rich plasma in patients with refractory erectile dysfunction: short-term outcomes and predictive value of mean platelet volume. Minerva Endocrinol (Torino) 2023. Online ahead of print.","DOI":"10.23736\/S2724-6507.23.04060-5"},{"key":"145024","doi-asserted-by":"crossref","unstructured":"Collins T, Alexander D, Barkatali B. Platelet-rich plasma: a narrative review. EFORT Open Rev 2021;6:225.","DOI":"10.1302\/2058-5241.6.200017"},{"key":"145025","doi-asserted-by":"crossref","unstructured":"Shen YX, Fan ZH, Zhao JG, Zhang P. The application of plateletrich plasma may be a novel treatment for central nervous system diseases. Med Hypotheses 2009;73:1038-40.","DOI":"10.1016\/j.mehy.2009.05.021"},{"key":"145026","doi-asserted-by":"crossref","unstructured":"Bava ED, Barber FA. Platelet-rich plasma products in sports medicine. Phys Sportsmed 2011; 39:94-9.","DOI":"10.3810\/psm.2011.09.1925"},{"key":"145027","unstructured":"White C, Brahs A, Dorton D, Witfill K. Platelet-rich plasma: A comprehensive review of emerging applications in medical and aesthetic dermatology. J Clin Aesthet Dermatol 2021;14:44."},{"key":"145028","doi-asserted-by":"crossref","unstructured":"Culha MG, Erkan E, Cay T, et al. The Effect of platelet-rich plasma on Peyronie\u2019s disease in rat model. Urol Int 2019;102:218-23.","DOI":"10.1159\/000492755"},{"key":"145029","doi-asserted-by":"crossref","unstructured":"D\u00f6nmez MI, Inci K, Zeybek ND, et al. The early histological effects of intravesical instillation of platelet-rich plasma in cystitis models. Int Neurourol J 2016;20:188.","DOI":"10.5213\/inj.1632548.274"},{"key":"145030","doi-asserted-by":"crossref","unstructured":"Cappelleri JC, Rosen RC, Smith MD, et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51.","DOI":"10.1016\/S0090-4295(99)00099-0"},{"key":"145031","doi-asserted-by":"crossref","unstructured":"Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 2011;60:1010-6.","DOI":"10.1016\/j.eururo.2011.07.053"},{"key":"145032","doi-asserted-by":"crossref","unstructured":"Cook CE. Clinimetrics corner: The Minimal Clinically Important Change Score (MCID): a necessary pretense. J Man Manip Ther 2008;16:E82.","DOI":"10.1179\/jmt.2008.16.4.82E"},{"key":"145033","doi-asserted-by":"crossref","unstructured":"Cavallo C, Roffi A, Grigolo B, et al. Platelet-rich plasma: the choice of activation method affects the release of bioactive molecules. Biomed Res Int. 2016;2016:6591717.","DOI":"10.1155\/2016\/6591717"},{"key":"145034","doi-asserted-by":"crossref","unstructured":"Anastasiadis E, Ahmed R, Khoja AK, Yap T. Erectile dysfunction: Is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence. Frontiers in Reproductive Health 2022:4:944765.","DOI":"10.3389\/frph.2022.944765"},{"key":"145035","doi-asserted-by":"crossref","unstructured":"Kakudo N, Morimoto N, Kushida S, et al. Platelet-rich plasma releasate promotes angiogenesis in vitro and in vivo. Med Mol Morphol 2014;47:83-9.","DOI":"10.1007\/s00795-013-0045-9"},{"key":"145036","doi-asserted-by":"crossref","unstructured":"Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1.Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.","DOI":"10.1016\/j.jclinepi.2010.04.026"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/12687\/12402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/12687\/12402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:17:21Z","timestamp":1727936241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/view\/12687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,2]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2024.12687","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}